![](https://static.biospace.com/dims4/default/2a3eb8e/2147483647/strip/true/crop/622x350+0+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fa1%2F02%2F2c650d36437ab56512bd7a298d14%2Fchina-vs-us-market.jpg)
BIOSECURE Act Could Signal a Seismic Shift for Biopharma in US and China
While the U.S. market is on an upswing this year with the biotech sector gaining 53.3% issuance in the first half of 2024 compared to the previous six months, the Chinese market has seen a 34.73% decrease in its biotech index over the last year. Whether …